Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II tria...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Clin Oncol
Autors principals: Miyawaki, Masayoshi, Naoki, Katsuhiko, Yoda, Satoshi, Nakayama, Sohei, Satomi, Ryosuke, Sato, Takashi, Ikemura, Shinnosuke, Ohgino, Keiko, Ishioka, Kota, Arai, Daisuke, Namkoong, Ho, Otsuka, Kengo, Miyazaki, Masaki, Tani, Tetsuo, Kuroda, Aoi, Nishino, Makoto, Yasuda, Hiroyuki, Kawada, Ichiro, Koh, Hidefumi, Nakamura, Morio, Terashima, Takeshi, Sakamaki, Fumio, Sayama, Koichi, Betsuyaku, Tomoko, Soejima, Kenzo
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403701/
https://ncbi.nlm.nih.gov/pubmed/28451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1154
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars